- Home
- OGI vs SKYE Comparison
OGI vs SKYE Comparison
Compare OGI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- SKYE
- Stock Information
- Founded
- OGI 2013
- SKYE 2012
- Country
- OGI Canada
- SKYE United States
- Employees
- OGI N/A
- SKYE N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- SKYE Health Care
- Exchange
- OGI Nasdaq
- SKYE Nasdaq
- Market Cap
- OGI 200.6M
- SKYE 94.0M
- IPO Year
- OGI N/A
- SKYE N/A
- Fundamental
- Price
- OGI $1.53
- SKYE $2.73
- Analyst Decision
- OGI
- SKYE Buy
- Analyst Count
- OGI 0
- SKYE 6
- Target Price
- OGI N/A
- SKYE $18.67
- AVG Volume (30 Days)
- OGI 820.8K
- SKYE 167.7K
- Earning Date
- OGI 02-11-2025
- SKYE 02-09-2025
- Dividend Yield
- OGI N/A
- SKYE N/A
- EPS Growth
- OGI N/A
- SKYE N/A
- EPS
- OGI N/A
- SKYE N/A
- Revenue
- OGI $118,317,480.00
- SKYE N/A
- Revenue This Year
- OGI $57.65
- SKYE N/A
- Revenue Next Year
- OGI $10.93
- SKYE N/A
- P/E Ratio
- OGI N/A
- SKYE N/A
- Revenue Growth
- OGI 0.69
- SKYE N/A
- 52 Week Low
- OGI $1.31
- SKYE $2.25
- 52 Week High
- OGI $2.91
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- OGI 44.32
- SKYE 37.40
- Support Level
- OGI $1.56
- SKYE $2.31
- Resistance Level
- OGI $1.77
- SKYE $3.04
- Average True Range (ATR)
- OGI 0.08
- SKYE 0.30
- MACD
- OGI -0.00
- SKYE 0.07
- Stochastic Oscillator
- OGI 11.11
- SKYE 44.68
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.